| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/12/2002 | US6355463 UDP-N-acetylenolpyruvylglucosamine reductase |
| 03/12/2002 | US6355446 DocosahexAenoic acid as retinoid X-receptor ligand and uses thereof |
| 03/12/2002 | US6355444 Detecting cancer marker in sample; obtain hybridoma sample, incubate with antibody, detect bound antibody |
| 03/12/2002 | US6355440 Detecting cell growth factors in sample; mix target sample with preferential receptors, detect binding, bound receptor indicates presence of cell growth factor in sample |
| 03/12/2002 | US6355275 Delivering an embolic agent formulation to a blood vessel to fill or plug the blood vessel and/or encourage clot formation so that blood flow through the vessel is reduced or ceases |
| 03/12/2002 | US6355270 Particles for oral delivery of peptides and proteins |
| 03/12/2002 | US6355268 Liposome-entrapped topoisomerase inhibitors |
| 03/12/2002 | US6355258 Method for formulating spill resistant pharmaceutical compositions in semi-solid form |
| 03/12/2002 | US6355251 Compositions and methods for epidermal chemexfoliation |
| 03/12/2002 | CA2347330C Liquid injectable formulation of disodium pamidronate |
| 03/12/2002 | CA2187214C Aminostilbazole derivative and medicine |
| 03/12/2002 | CA2034741C Therapeutic antibody based fusion proteins |
| 03/07/2002 | WO2002018948A2 Differentially expressed epitopes and uses thereof |
| 03/07/2002 | WO2002018637A2 Diagnosis and treatment of prostate cancer |
| 03/07/2002 | WO2002018623A2 Methods and reagents for protease inhibition |
| 03/07/2002 | WO2002018608A2 Methods for enhancing the efficacy of cancer therapy |
| 03/07/2002 | WO2002018593A2 Modulation of fas and fasl expression |
| 03/07/2002 | WO2002018585A2 Packaging of positive-strand rna virus replicon particles |
| 03/07/2002 | WO2002018582A2 62112, a novel human dehydrogenase and uses thereof |
| 03/07/2002 | WO2002018581A2 G-protein coupled receptors |
| 03/07/2002 | WO2002018576A2 Compositions and methods relating to lung specific genes |
| 03/07/2002 | WO2002018575A2 Genes expressed in the cell cycle |
| 03/07/2002 | WO2002018557A2 Human kinases |
| 03/07/2002 | WO2002018554A2 Isolated human drug-metabolizing proteins, nucleic acid moleculesand uses thereof |
| 03/07/2002 | WO2002018553A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 03/07/2002 | WO2002018544A2 Method and reagents for treatment of skin disorders by modulating the notch pathway |
| 03/07/2002 | WO2002018540A2 Pyridine derivatives useful as cd40:cd154 binding interruptor compounds and use thereof to treat immunological complications |
| 03/07/2002 | WO2002018536A2 Truncated bard1 protein, and its diagnostic and therapeutic uses |
| 03/07/2002 | WO2002018450A1 New cross-linked derivatives of hyaluronic acid |
| 03/07/2002 | WO2002018448A2 Percarboxylated polysaccharides, and a process for their preparation |
| 03/07/2002 | WO2002018445A2 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| 03/07/2002 | WO2002018440A1 Anti-angiogenic peptides |
| 03/07/2002 | WO2002018438A1 Modified proteins, isolated novel peptides, and uses thereof |
| 03/07/2002 | WO2002018422A1 Amino acid substitution mutants of interleukin 13 |
| 03/07/2002 | WO2002018404A2 Nucleoside derivatives for the treatment of hepatitis c |
| 03/07/2002 | WO2002018395A1 Phosphate derivatives as immunoregulatory agents |
| 03/07/2002 | WO2002018389A2 Thienopyrimidine |
| 03/07/2002 | WO2002018386A1 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a]PYRIMIDIN-5(1H)ONE DERIVATI VES |
| 03/07/2002 | WO2002018385A1 1-[ALKYL], 1-[(HETEROARYL)ALKYL] AND 1-[(ARYL)ALKYL]-7-PYRIDINYL-IMIDAZO[1,2-a]PYRIMIDIN-5(1H)-ONE DERIVATIVES |
| 03/07/2002 | WO2002018383A2 Aza heterocyclic derivatives and their therapeutic use |
| 03/07/2002 | WO2002018379A2 7-oxo pyridopyrimidines |
| 03/07/2002 | WO2002018377A1 Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists |
| 03/07/2002 | WO2002018373A1 Quinazoline derivatives, medicaments containing these compounds, their use, and methods for the production thereof |
| 03/07/2002 | WO2002018371A1 Nucleoside metabolism inhibitors |
| 03/07/2002 | WO2002018370A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof |
| 03/07/2002 | WO2002018368A1 Tricyclic antitumor compounds being farnesyl protein transferase inhibitors |
| 03/07/2002 | WO2002018361A2 Compounds having activity as inhibitors of cytochrome p450rai |
| 03/07/2002 | WO2002018346A1 Pyrazole derivatives and their use as protein kinase inhibitors |
| 03/07/2002 | WO2002018340A1 GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS |
| 03/07/2002 | WO2002017968A2 Sensitization of cancer cells to immunoconjugate-induced cell death by transfection with il-13 receptor alpha chain-2 |
| 03/07/2002 | WO2002017967A1 Method of increasing testosterone and related steroid concentrations in women |
| 03/07/2002 | WO2002017952A2 Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma |
| 03/07/2002 | WO2002017951A1 Method for treating the central nervous system by administration of igf structural analogs |
| 03/07/2002 | WO2002017946A1 Bioactive fraction of eurycoma longifolia |
| 03/07/2002 | WO2002017935A2 A method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease |
| 03/07/2002 | WO2002017927A1 Method for treating erectile dysfunction and increasing libido in men |
| 03/07/2002 | WO2002017914A2 Fused pyrrolocarbazoles against inflammation |
| 03/07/2002 | WO2002017910A1 Agents for neutron capture therapy |
| 03/07/2002 | WO2002017904A1 Use of asiatic acid or asiaticoside for treatment of cancer |
| 03/07/2002 | WO2002017897A2 Methods for treating tumors using sulfonyl compounds |
| 03/07/2002 | WO2002017892A2 Water-dispersible encapsulated sterols |
| 03/07/2002 | WO2002017878A1 Lung surfactant compositions with dynamic swelling behaviour |
| 03/07/2002 | WO2002017857A2 Methods and compositions for inhibiting angiogenesis |
| 03/07/2002 | WO2002017852A2 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
| 03/07/2002 | WO2001094420B1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 03/07/2002 | WO2001090103A9 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators |
| 03/07/2002 | WO2001090096A3 Triterpenoid derivatives and their use as antiproliferative agents |
| 03/07/2002 | WO2001087329A8 Liquid pharmaceutical composition containing an erythropoietin derivate |
| 03/07/2002 | WO2001079269A3 Lipid binding protein 4 |
| 03/07/2002 | WO2001078649A3 Pharmaceutical curative compound |
| 03/07/2002 | WO2001077181A3 Anti-rhesus d monoclonal antibodies |
| 03/07/2002 | WO2001077100A3 Benzoamide piperidine compounds as substance p antagonists |
| 03/07/2002 | WO2001074855A3 Compositions and methods for dendritic cell-based immunotherapy |
| 03/07/2002 | WO2001072330A3 Method for immunostimulation using binding agents for the fc rec eptor of immunoglobulin a and for cancer cells or infections antigen |
| 03/07/2002 | WO2001068122A3 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity 'mia' |
| 03/07/2002 | WO2001068033A3 Il-8 receptor antagonists |
| 03/07/2002 | WO2001064226A3 Farnesyl protein transferase inhibitor combinations with platinum compounds |
| 03/07/2002 | WO2001064194A3 Farnesyl protein transferase inhibitor combinations with camptothecin compounds |
| 03/07/2002 | WO2001059130A3 Proteins producing an altered immunogenic response and methods of making and using the same |
| 03/07/2002 | WO2001058956A3 Antibodies that bind human interleukin-18 and methods of making and using |
| 03/07/2002 | WO2001058949A3 Heterologous polypeptide of the tnf family |
| 03/07/2002 | WO2001057233A3 Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides |
| 03/07/2002 | WO2001057022A3 Pyrazole compositions useful as inhibitors of erk |
| 03/07/2002 | WO2001056599A3 Hyperthermia and immunotherapy for leukemias, lymphomas, and solid tumors |
| 03/07/2002 | WO2001055692A3 Neurosteroids as markers for alzheimer's disease |
| 03/07/2002 | WO2001055219A3 scsCNTFR/NNT-1 FUSION PROTEIN |
| 03/07/2002 | WO2001055178A3 Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer |
| 03/07/2002 | WO2001055131A3 Prodigiosin-derivatives as neoplastic and anti-viral agents |
| 03/07/2002 | WO2001055092B1 5-aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents |
| 03/07/2002 | WO2001054716A3 Genetically engineered tumor cell vaccines |
| 03/07/2002 | WO2001053468A3 Lipid metabolism enzymes and polynucleotides encoding them |
| 03/07/2002 | WO2001051636A3 Secreted proteins |
| 03/07/2002 | WO2001046231A3 Polynucleotides and polypeptides encoded thereby |
| 03/07/2002 | WO2001044808A3 Methods of diagnosis and treatment by binding p75/airm1 |
| 03/07/2002 | WO2001043772A3 Method and device for producing an autologous immunization vaccine against cancerous diseases (tumour vaccine) |
| 03/07/2002 | WO2001042285A3 Extracellular matrix and cell adhesion proteins as well as genes encoding them |
| 03/07/2002 | WO2001036686A3 Genomic polymorphism for predicting therapeutic response |
| 03/07/2002 | WO2001034645A3 Mutated il-13 molecules and their uses |
| 03/07/2002 | WO2001032888A3 Human transferase molecules |
| 03/07/2002 | WO2001029220A3 Mage-a12 antigenic peptides and uses thereof |